1. **ID2-mediated PV repression**
- **Weaknesses:** The chain `AD -> ID2 up -> PV loss + PGC-1α suppression -> PV dysfunction` is mostly stitched from developmental or non-AD data, not direct adult AD PV-interneuron causality. The key gap is cell-type specificity: adult PV dysfunction in AD has not been shown to be driven by ID2 in vivo.
- **Counter-evidence:** PGC-1α itself is reduced in AD brain, but that does not identify ID2 as the upstream cause ([PMID:19273754](https://pubmed.ncbi.nlm.nih.gov/19273754/)). AD-linked APP/AICD signaling can also *increase* PGC-1α expression, arguing against a simple monotonic repression model ([PMID:24304563](https://pubmed.ncbi.nlm.nih.gov/24304563/)). Early AD models can show **PV interneuron hyperactivity**, not just PV loss/silencing ([PMID:40913114](https://pubmed.ncbi.nlm.nih.gov/40913114/), [PMID:41269883](https://pubmed.ncbi.nlm.nih.gov/41269883/)).
- **Alternative explanations:** PV changes may be secondary to amyloid, sodium-channel dysfunction, perineuronal-net loss, or altered excitatory drive rather than ID2-dependent fate repression.
- **Key falsification experiments:** Measure ID2 specifically in PV neurons from human AD snRNA-seq/snATAC and AD mice; CRISPRi/knockdown ID2 only in adult PV cells; test whether PV markers, firing, and mitochondrial respiration recover independently of amyloid burden.
- **Revised confidence:** **0.27**
2. **LDHB upregulation to boost lactate oxidation in PV interneurons**
- **Weaknesses:** This depends on a strong astrocyte-neuron lactate-shuttle interpretation and assumes LDHB is the rate-limiting node in PV metabolism. Neither is established in AD.
- **Counter-evidence:** Neuronal activity has been reported to correlate better with **glucose** than lactate utilization ([PMID:19393013](https://pubmed.ncbi.nlm.nih.gov/19393013/)). The energetic centrality of the astrocyte-neuron lactate shuttle remains explicitly contested ([PMID:28151548](https://pubmed.ncbi.nlm.nih.gov/28151548/), [PMID:29292507](https://pubmed.ncbi.nlm.nih.gov/29292507/)). LDHB loss impairs long-term memory, but the phenotype is not PV-specific and neuropathology is mild, so the therapeutic leverage may be limited ([PMID:39566837](https://pubmed.ncbi.nlm.nih.gov/39566837/)).
- **Alternative explanations:** If PV cells are metabolically stressed, bottlenecks may sit at glucose uptake, MCT2 transport, mitochondrial ETC capacity, Na+/K+ ATPase load, or synaptic ion-channel programs rather than LDHB itself.
- **Key falsification experiments:** PV-cell-specific LDHB overexpression in AD mice with direct flux tracing (`13C-lactate` vs `13C-glucose`), plus patch-clamp and gamma-oscillation rescue. If glucose remains the dominant substrate and PV physiology does not improve, the hypothesis fails.
- **Revised confidence:** **0.22**
3. **PARP1 hyperactivation drives NAD+ depletion and disables NAMPT-SIRT1 in microglia**
- **Weaknesses:** The first half is plausible; the second half is overclaimed. “PARP1 consumes NAD+” is established, but “therefore NAMPT salvage is disabled and microglial SASP is amplified” is not yet a demonstrated causal sequence in AD microglia.
- **Counter-evidence:** PARP1 also has normal neuronal functions in DNA repair, memory-related transcriptional responses, and sleep-linked genome maintenance ([PMID:34798058](https://pubmed.ncbi.nlm.nih.gov/34798058/), [PMID:38750651](https://pubmed.ncbi.nlm.nih.gov/38750651/)). Impaired or inactive PARP1 can itself cause genome instability ([PMID:37487079](https://pubmed.ncbi.nlm.nih.gov/37487079/), [PMID:11444840](https://pubmed.ncbi.nlm.nih.gov/11444840/)).
- **Alternative explanations:** NAD+ loss in neurodegeneration may be driven more by CD38, mitochondrial dysfunction, chronic inflammation, or reduced precursor availability than by PARP1 alone.
- **Key falsification experiments:** In AD microglia, quantify whether PARP1 inhibition actually restores NAMPT flux, NAD+, SIRT1 activity, and reduces SASP without worsening DNA damage markers. Separate microglial-specific from neuronal PARP1 inhibition.
- **Revised confidence:** **0.39**
4. **Astrocytic MCT1 failure impairs lactate delivery to PV interneurons**
- **Weaknesses:** The hypothesis is too cell-biologically narrow. MCT1 is not simply an “astrocyte exporter”; in CNS it is also prominent in oligodendroglia, endothelium, and other glial compartments.
- **Counter-evidence:** CNS MCT1 is strongly expressed in oligodendroglia and is required for axonal support ([PMID:22801498](https://pubmed.ncbi.nlm.nih.gov/22801498/), [PMID:33440165](https://pubmed.ncbi.nlm.nih.gov/33440165/)). In adult human cortex, MCT1 is also abundant in blood vessels and astrocytes, arguing against a uniquely astrocytic explanation ([PMID:16403470](https://pubmed.ncbi.nlm.nih.gov/16403470/), [PMID:9252498](https://pubmed.ncbi.nlm.nih.gov/9252498/)).
- **Alternative explanations:** AD lactate-handling defects may be dominated by endothelial transport, oligodendrocyte support, neuronal MCT2, or broader mitochondrial dysfunction rather than astrocytic MCT1 export to PV cells.
- **Key falsification experiments:** Use astrocyte-specific vs oligodendrocyte-specific MCT1 rescue in AD models; measure PV-cell lactate uptake, firing, and gamma rhythms. If astrocyte-only rescue fails while oligodendrocyte rescue works, the proposed mechanism is wrong.
- **Revised confidence:** **0.25**
5. **ERRα agonism to drive mitochondrial biogenesis in PV interneurons**
- **Weaknesses:** The pharmacology is shaky and the PV/AD evidence chain is indirect. The cited tool compound `GSK4716` is classically an **ERRβ/γ** agonist, not a validated ERRα agonist.
- **Counter-evidence:** The ERR field has long lacked effective selective chemical tools for ERRα agonism; even medicinal chemistry papers frame ERRα agonism as underdeveloped ([PMID:32683181](https://pubmed.ncbi.nlm.nih.gov/32683181/), [PMID:18778951](https://pubmed.ncbi.nlm.nih.gov/18778951/)). GSK4716 is used as an ERRγ agonist in neural studies, not as an ERRα-selective probe ([PMID:32173553](https://pubmed.ncbi.nlm.nih.gov/32173553/), [PMID:19746993](https://pubmed.ncbi.nlm.nih.gov/19746993/)).
- **Alternative explanations:** PV vulnerability may reflect ion-channel and synaptic-release defects, perineuronal-net loss, or amyloid-driven circuit imbalance more than insufficient ERRα-mediated biogenesis.
- **Key falsification experiments:** First prove target engagement with a real ERRα-selective agonist or PV-specific ESRRA overexpression; then test mitochondrial respiration, spike fidelity, and cognition in AD models. If rescue requires ERRγ or broad metabolic changes, the ERRα hypothesis collapses.
- **Revised confidence:** **0.18**
6. **C1q-independent, C3-redirecting complement therapy to protect PV basket-cell synapses**
- **Weaknesses:** This assumes complement is mostly harmful at PV synapses and can be “retuned” without major tradeoffs. But C3 has both harmful synapse-tagging and beneficial plaque-clearance roles.
- **Counter-evidence:** C3 deficiency can **accelerate amyloid deposition and neurodegeneration**, consistent with a protective clearance function ([PMID:18562603](https://pubmed.ncbi.nlm.nih.gov/18562603/)). Yet in later plaque-rich APP/PS1 mice, C3 loss can preserve synapses and cognition despite more plaques, showing the biology is stage-dependent rather than directionally simple ([PMID:28566429](https://pubmed.ncbi.nlm.nih.gov/28566429/)). Complement-mediated injury may also extend through MAC, not just C3 opsonization ([PMID:35794654](https://pubmed.ncbi.nlm.nih.gov/35794654/)).
- **Alternative explanations:** PV synapse loss may be driven by microglial activation, perineuronal-net degradation, or activity-dependent remodeling with complement as a context-dependent amplifier, not the master cause ([PMID:32745992](https://pubmed.ncbi.nlm.nih.gov/32745992/)).
- **Key falsification experiments:** Test stage-specific, compartment-specific inhibition: C1q, C3, CR3, and MAC blockade, with direct quantification of PV perisomatic synapses, plaque burden, and infection susceptibility. If synapse rescue comes with worse amyloid handling, the proposed therapeutic framing is too naive.
- **Revised confidence:** **0.31**
7. **Astrocytic xCT/SLC7A11 dysfunction causes PV oxidative stress and excitotoxicity**
- **Weaknesses:** The directionality is internally unstable. Increasing xCT can raise cystine import and glutathione, but also raises extracellular glutamate release; decreasing xCT can reduce glutamate-driven toxicity but impair redox buffering.
- **Counter-evidence:** Microglial/system xc- activity can itself mediate glutamate-dependent neurotoxicity ([PMID:17475885](https://pubmed.ncbi.nlm.nih.gov/17475885/), [PMID:38057869](https://pubmed.ncbi.nlm.nih.gov/38057869/)). Sulfasalazine is not a clean argument for “xCT inhibition is bad”: it can be neuroprotective through NMDA-receptor antagonism ([PMID:12649352](https://pubmed.ncbi.nlm.nih.gov/12649352/)). So the proposed simple “activate xCT = less excitotoxicity” logic is not secure.
- **Alternative explanations:** Oxidative stress in PV cells may come more from mitochondrial ROS, impaired glutamate uptake by EAATs, microglial cytokines, or perineuronal-net disruption than from xCT deficiency per se.
- **Key falsification experiments:** Cell-type-specific manipulation of xCT in astrocytes vs microglia in AD models, with simultaneous measures of extracellular glutamate, glutathione, PV firing, and survival. If astrocytic xCT activation improves GSH but worsens glutamate stress, the hypothesis fails as therapy.
- **Revised confidence:** **0.20**
**Bottom line:** The two least weak are still **PARP1** and **complement**, but both are highly context-dependent and not yet mechanistically tight enough for confident prioritization. My revised ranking would be: `PARP1 > complement > ID2 > MCT1 > LDHB > xCT > ERRα`.